Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Bayer Stops Sale of Glucose Meter Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2013 | 12:07pm CEST

By Hendrik Varnholt

FRANKFURT--German pharmaceutical company Bayer AG (>> Bayer AG) will retain its blood glucose meter business, a spokeswoman said Wednesday, confirming a Bloomberg report.

Bayer had put up the unit for sale and had been in talks with French peer Sanofi SA (>> SANOFI) about a deal which could have been valued at around $1.5 billion, people familiar with the matter told Dow Jones Newswires in December.

"We have evaluated several options and decided to retain it," Bayer HealthCare chief Joerg Reinhardt said about the glucose meter business, according to Bloomberg.

Natali Schwab, Eyk Henning and Dana Cimilluca contributed to this story.

Write to Hendrik Varnholt at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bayer AG, SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
09:19a BAYER : Receives Approval for Stivarga® in Japan for Second-Line Treatment of He..
06/23 BAYER : Receives Positive CHMP Opinion for regorafenib for the Second-Line Syste..
06/22 COVESTRO : Patent Issued for Electrocatalyst, Electrode Coating and Electrode fo..
06/22 BAYER : Patent Issued for Stable, Concentrated Herbicidal Compositions (USPTO 96..
06/22 Ethisphere Teams with Leaders from Top Companies to Drive Business Ethics
06/22 COVESTRO : U.S. Patents Awarded to Inventors in West Virginia (June 22)
06/22 COVESTRO : U.S. Patents Awarded to Inventors in Georgia (June 22)
06/21 Sore Throat Remedies Market 2017 - Pfizer, Novartis, Bayer AG, AstraZeneca, P..
06/20 Novartis eye drug works with fewer injections than rival
06/20 COVESTRO : LLC President to Co-Lead Sustainable Pittsburgh’s ‘CEOs f..
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/23 European Ad Com backs Bayer's regorafenib for second-line liver cancer
06/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 23, 2017
06/22 Bayer AG (BAYZF) Presents At Citi European Healthcare Conference - Slideshow
06/20 Novartis wet AMD candidate brolucizumab matches Eylea in late-stage studies w..
06/18 MONSANTO : Majority Of Polled Americans Oppose Bayer Acquisition (Will It Matter..
Advertisement
Financials (€)
Sales 2017 49 998 M
EBIT 2017 9 698 M
Net income 2017 5 742 M
Debt 2017 10 783 M
Yield 2017 2,35%
P/E ratio 2017 18,53
P/E ratio 2018 17,23
EV / Sales 2017 2,23x
EV / Sales 2018 2,08x
Capitalization 100 805 M
More Financials
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 118 €
Spread / Average Target -3,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER22.97%112 730
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results